Chemomab delays Phase 3 clinical trial after merger

Genfit's competitor, Chemomab, postpones its Phase 3 clinical trial for primary sclerosing cholangitis.

Published 1sem1 sourceNotableupdated 1sem

≈ 18sSpeed

The fact

A merger with another biotech delays the originally planned 2026 timeline.

Genfit may capitalize on this to advance its own research on the same disease.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on July 9, 2026